KAN-001 Moves Into Phase 1 Testing in PD-L1-Positive Non-Small Cell Lung Cancer
A new Phase 1 study is set to examine whether KAN-001, an investigational live biotherapeutic product, can be paired safely with pembrolizumab in adults with PD-L1-positive, inoperable or metastatic non-small cell lung cancer. The trial also allows a chemotherapy backbone in one cohort, setting up an early look at how a microbiome-based intervention might behave alongside standard systemic therapy in a disease where immune responsiveness remains uneven.
The study is designed first around safety and tolerability, but the biologic premise is more ambitious than a simple add-on trial. KAN-001 is being evaluated after bowel preparation, with investigators also asking whether the microbial strains in the product can be detected in stool after treatment. In practical terms, the trial is probing whether an engineered or selected microbial signal can survive the gut environment long enough to engraft, or at least persist, while patients receive checkpoint blockade every 3 weeks.
One sentence captures the whole wager: this trial is asking whether altering the gut ecosystem can improve the therapeutic reach of immunotherapy in lung cancer.
A Microbiome Strategy Added to Checkpoint Blockade
The study is officially titled a Phase 1 trial to evaluate safety, tolerability, and engraftment of KAN-001 in combination with pembrolizumab, with or without chemotherapy, in participants with PD-L1-positive non-small cell lung cancer. Enrollment is estimated at 40 participants, and the start date is projected for 2026-11. Primary completion and study completion are both estimated for 2029-12.
The design reflects a growing oncology hypothesis: the gut microbiome can shape response to immune checkpoint inhibitors. In lung cancer, where pembrolizumab has become a backbone therapy for many patients with PD-L1 expression, the remaining challenge is not whether the drug works, but why some tumors remain resistant or only partially responsive. A live biotherapeutic product offers a direct way to influence microbial composition rather than attempting indirect modulation through diet or supportive care alone.
Participants will complete a bowel preparation before the first dose of KAN-001. After that, the regimen includes a loading dose followed by maintenance dosing every 3 weeks. Pembrolizumab is also administered every 3 weeks, and some participants will receive chemotherapy as well. The study includes blood, stool, and stool-wipe sampling, along with a gastrointestinal symptom diary and imaging assessments to track cancer status, health, and safety.
Why the Eligibility Rules Are Narrow
The inclusion criteria make clear that investigators are trying to reduce biologic noise. Participants must have histologically or cytologically confirmed non-small cell lung cancer, inoperable or metastatic disease measurable by RECIST v1.1, and an ECOG performance status of 0 or 1. They also must be eligible for one of three cohort-specific pathways tied to PD-L1 expression and prior treatment history.
Cohort 1 includes participants not receiving chemotherapy who have a PD-L1 tumor proportion score of at least 50% and no prior systemic therapy for inoperable or metastatic disease. Cohort 2 includes participants receiving chemotherapy who are PD-L1 positive with a TPS of at least 1% and have had no prior systemic therapy for advanced disease. Cohort 3 includes participants with PD-L1 TPS of at least 1%, documented disease progression after at least four cycles of immune checkpoint inhibitor therapy combined with chemotherapy, a last checkpoint inhibitor dose within 60 days before baseline, and progression confirmed by a second CT scan at least 4 weeks later.
The exclusion criteria are just as revealing. Prior use of a live biotherapeutic product or fecal microbiota transplant within the past year is excluded, as are probiotics within 14 days and antibiotics within 7 days before KAN-001 administration. A live vaccine within 30 days before pembrolizumab is also disallowed. These restrictions matter because the trial is trying to observe whether KAN-001 can colonize or persist in a relatively unperturbed microbial environment; antibiotics, probiotics, and recent microbiome-based therapies could blur that signal.
Safety, Engraftment, and the Real-World Constraints of Microbiome Oncology
The primary questions are straightforward: what side effects occur when KAN-001 is given with pembrolizumab, with or without chemotherapy, and can the strains contained in KAN-001 be detected in stool after treatment? In a Phase 1 oncology study, that combination of endpoints tells a larger story. Safety has to be established before any biologic effect can be interpreted, but stool detection will be the first practical readout of whether the product reaches its intended ecological niche.
Because the intervention is live and oral, the protocol also screens for gastrointestinal stability. Prior large bowel surgery, active GI disorders such as uncontrolled vomiting or diarrhea, inflammatory bowel disease requiring treatment within six months, and active GI parasitic infection all sit on the exclusion list. These conditions could make microbial engraftment less predictable and could also increase the chance that GI toxicity is misattributed to the wrong cause. A person with unstable gut function is not an ideal host for a therapy whose mechanism depends on intestinal persistence.
The size 0 capsule requirement is another small but telling detail. Microbiome therapeutics often carry formulation constraints that are irrelevant in conventional oncology drugs. The oral route creates an entirely different set of operational barriers, from capsule swallowing to bowel preparation to adherence with timed dosing.
What the Trial Could Clarify for Immunotherapy in Lung Cancer
If KAN-001 proves tolerable with pembrolizumab, the next layer of interest will be whether the product measurably alters the intestinal microbiome in a way that can be tracked in stool. A positive signal there would not prove clinical benefit, but it would validate the concept that a live biotherapeutic can be delivered alongside immune checkpoint blockade in a population already managing metastatic or inoperable disease.
The possible synergy is biologically plausible. Immune checkpoint blockade depends on antigen presentation, T-cell activation, and a host environment capable of sustaining anti-tumor immune activity. The gut microbiome has been linked to immune tone, systemic inflammation, and the balance between immune activation and tolerance. In theory, a well-chosen microbial product could tilt that balance toward a more favorable response to pembrolizumab, and perhaps even help in patients receiving chemotherapy by countering some of the immune dampening that accompanies cytotoxic treatment.
The study still comes with built-in caution. It excludes patients with life expectancy under 4 months, symptomatic or unstable brain metastases, leptomeningeal disease, solid-organ transplantation, and a range of laboratory or infectious issues that could complicate interpretation. Those limits are appropriate for an early trial, but they also mean the results will come from a selected subset of patients with relatively preserved functional status.
This is an early test of a treatment concept, not a practice-changing result. The real clinical question will be whether stool engraftment, tolerability, and immune-based cancer control can align in the same cohort without creating a toxic or unstable GI profile.
Study Footprint and Site Structure
The trial lists two study locations: Taylor Cancer Research Center in Maumee, Ohio, and Centre hospitalier de l’Université de Montréal (CHUM) in Montreal, Quebec. The sponsor is Kanvas Biosciences, and the listed ClinicalTrials.gov ID is NCT07910942.
At this stage, there are no results posted. The next meaningful readouts will come from whether the combination can be administered safely, whether KAN-001 can be detected after dosing, and whether the different cohort structures generate usable early signals in PD-L1-positive disease. Those data will determine whether this microbiome-centered approach can move beyond an interesting biologic idea and into a larger oncology development program.